• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    K Health Expands Board and Executive Team Amid Continued Demand for Virtual Care

    5/19/21 9:00:00 AM ET
    $TEVA
    $SGFY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Retail: Computer Software & Peripheral Equipment
    Technology
    Get the next $TEVA alert in real time by email

    Healthcare Veteran and General Counsel Join Company to Support Growing Momentum

    K Health, the 24/7 primary care system, announced today the appointment of Vivian Riefberg to its board. Riefberg is a board member at Johns Hopkins Medicine, PBS, and Signify Health (NYSE:SGFY) and the former co-leader of the health services practice at McKinsey & Company. K Health also announced that Chen Yehudai, former Vice President and General Counsel at Teva Pharmaceuticals (NYSE:TEVA), has joined its executive team as the company's first General Counsel.

    With over 4 million users, K Health's base continues to grow, with demand increasing rapidly since the start of the pandemic. Riefberg and Yehudai will help scale and develop the product in anticipation of continued growth.

    Vivian Riefberg brings over 30 years of experience in the global healthcare industry to the K Health board of directors. As a Senior Partner and former board member at McKinsey & Company, she co-led the firm's health services practice, led the public sector practice, and spent more than three decades serving clients across the healthcare ecosystem. She is a Professor of Practice at the University of Virginia Darden School of Business and a Director Emeritus at McKinsey & Company.

    "K Health has the potential to reduce annual medical costs by billions of dollars through its approach to tackling the biggest healthcare issues," said Riefberg. "With partnerships involving the largest players in the industry, I am honored to join a company that is working towards providing affordable, convenient and quality care to millions of people, especially as we navigate through the COVID-19 pandemic and beyond."

    "We're thrilled for Vivian to bring a unique and fresh perspective to our board," said Allon Bloch, K Health's CEO and co-founder. "She's joining a passionate group of similar-minded people who, like everyone at K, are dedicated to changing how we all approach healthcare."

    Chen Yehudai joins K Health as its first General Counsel. In this role, Yehudai will lead K Health's legal and compliance functions. She previously spent more than 13 years at Teva Pharmaceuticals, where she was the Vice President and General Counsel of Global Antitrust and Global HR and Corporate Affairs. Prior to Teva she was an Associate at Skadden, Arps, Slate, Meaghar & Flom in New York City. She holds an LL.M. and a doctoral degree (JSD) from Columbia University School of Law.

    Last month, K Health announced the formation of Hydrogen Health, a joint venture with Anthem and Blackstone to advance high quality digital and affordable healthcare. In January 2021, K Health announced K Pediatrics, an offering with insights and care for children aged 3-17 that's free with a K Health membership. K Health has also partnered with Baltimore City Public Schools, Boost Mobile, and Louisiana State University in an effort to make 24/7 access to doctors a reality for everyone in the U.S.

    About K Health

    K Health, headquartered in New York, is the digital healthcare company on a mission to use the power of shared knowledge to get everyone access to better, affordable healthcare—whenever, wherever they need it. K Health is a free tool that uses AI to help people understand how doctors diagnose and treat those with similar symptoms and conditions (aka "People Like Me"). Its data-driven platform consolidates the knowledge of thousands of doctors and billions of clinical data insights to get people trusted information and treatment. K Health also offers the option to chat with a clinician without insurance for less than a copay. K Health treats almost all primary care conditions, as well as anxiety and depression, and offers customizable treatment plans and prescriptions.

    Frequently the #1 downloaded app in the App Store's medical category, K Health is available in all 50 states and has helped over 4 million people get access to higher quality and affordable care. For more information, please visit www.khealth.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20210519005263/en/

    Get the next $TEVA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TEVA
    $SGFY

    CompanyDatePrice TargetRatingAnalyst
    Teva Pharmaceutical Industries Limited
    $TEVA
    6/6/2025$24.00Buy
    Goldman
    Teva Pharmaceutical Industries Limited
    $TEVA
    5/28/2025$25.00Buy
    Truist
    Teva Pharmaceutical Industries Limited
    $TEVA
    5/12/2025$23.00Neutral → Overweight
    Analyst
    Teva Pharmaceutical Industries Limited
    $TEVA
    7/10/2024$20.00Hold → Buy
    Argus
    Teva Pharmaceutical Industries Limited
    $TEVA
    3/8/2024$14.00Underweight → Neutral
    JP Morgan
    Teva Pharmaceutical Industries Limited
    $TEVA
    2/12/2024$12.00 → $19.00Neutral → Overweight
    Piper Sandler
    Teva Pharmaceutical Industries Limited
    $TEVA
    1/23/2024$10.00 → $14.00Hold → Buy
    Jefferies
    Teva Pharmaceutical Industries Limited
    $TEVA
    1/3/2024$8.00 → $12.00Underweight → Neutral
    Piper Sandler
    More analyst ratings

    $TEVA
    $SGFY
    Financials

    Live finance-specific insights

    See more
    • Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved

      For an accessible version of this Press Release, please visit www.tevapharm.com On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy; Q1 2025 shows ninth consecutive quarter of revenue growth, excluding revenues recorded for Sanofi collaboration.Q1 2025 revenues of $3.9 billion, an increase of 5%; net of $100 million foreign exchange impact, reported revenues growth of 2%.AUSTEDO® – shows continued strong growth, with worldwide revenues of $411 million in Q1 2025, an increase of 39% in local currency terms compared to Q1 2024; increasing 2025 full-year revenue outlook from ~$1.9-2.05 billion to $1.95-2.05 billion.AJOVY® – global revenues of $139 million

      5/7/25 7:00:00 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City

      TEL AVIV, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will host Innovation & Strategy Day on Thursday, May 29, 2025 to discuss the acceleration phase of its strategy and portfolio priorities. The event will take place in New York, N.Y. Presentations will begin at 8:30 a.m. Eastern Time and are expected to conclude at 12:30 p.m. Eastern Time. Richard Francis, Teva's President and CEO, along with other members of the executive management team will discuss an update on the strategy and key priorities focusing on growth and innovation. Due to limited capacity, in-person attendance is by invitation only. Analysts a

      5/7/25 7:00:00 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025

      TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2025 financial results on Wednesday, May 7, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations. Following the conclusion of the call, a replay of the webcast will be available within 24 hou

      3/27/25 4:30:00 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TEVA
    $SGFY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Teva Pharmaceutical Industries Limited

      SC 13G - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)

      11/12/24 10:34:14 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Teva Pharmaceutical Industries Limited (Amendment)

      SC 13G/A - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)

      4/9/24 10:26:26 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Teva Pharmaceutical Industries Limited

      SC 13G - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)

      2/1/24 8:03:56 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TEVA
    $SGFY
    SEC Filings

    See more
    • SEC Form 8-K filed by Teva Pharmaceutical Industries Limited

      8-K - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)

      6/5/25 4:52:32 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SD filed by Teva Pharmaceutical Industries Limited

      SD - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)

      6/2/25 4:06:38 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva Pharmaceutical Industries Limited filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

      8-K - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)

      5/28/25 4:11:41 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TEVA
    $SGFY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Global Operations Shields Matthew sold $105,628 worth of Ordinary Shares (6,206 units at $17.02) and converted options into 16,195 units of Ordinary Shares (SEC Form 4)

      4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

      6/5/25 5:08:56 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by EVP, Business Development Lippman Evan

      4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

      5/19/25 4:00:40 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • See "Remarks" Sabag Mark sold $6,097,304 worth of Ordinary Shares (337,915 units at $18.04), decreasing direct ownership by 69% to 150,996 units (SEC Form 4)

      4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

      5/12/25 4:00:58 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TEVA
    $SGFY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

      TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today the pricing and early acceptance results of its previously announced tender offers (the "Offers") to purchase for cash the outstanding notes issued by finance subsidiaries of Teva and guaranteed by Teva of the series described in the table below (the "Notes") upon the terms of, and subject to the conditions as set out in, the Offer to Purchase, dated May 19, 2025 (the "Offer to Purchase"). Capitalized terms used in this announcement but not otherwise defined shall have the meanings given to them in the Offer to Purchase. Upon the terms and subjec

      6/3/25 5:30:00 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

      TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today the early tender results in connection with its previously announced tender offers (the "Offers") as specified below for the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva: USD 3.150% Senior Notes due 2026, CUSIP 88167AAE1 / ISIN US88167AAE10 (Registered), issued by Teva Pharmaceutical Finance Netherlands III B.V. (the "Pool 1 Notes");USD 4.750% Sustainability-Linked Senior Notes due 2027, CUSIP 88167AAP6 / ISIN US88167AAP66 (Registered), issued by Teva Pharmaceutical Finance Netherlands III B.V. (the "Priority 2 No

      6/3/25 7:15:47 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

      More than half of residents with tardive dyskinesia (TD) residing in long-term care (LTC) settings do not receive standard of care treatment, and one-quarter are left untreatedLTC residents are often given a broader diagnosis of extrapyramidal syndrome, which can lead to incorrect treatment options for TD Teva is committed to continuing to advance research to better understand and help address unmet needs among patients living with TD in LTC settings as well as other settings PARSIPPANY, N.J. and TEL AVIV, Israel, May 30, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from a study of tre

      5/30/25 9:05:00 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TEVA
    $SGFY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Teva Pharma with a new price target

      Goldman initiated coverage of Teva Pharma with a rating of Buy and set a new price target of $24.00

      6/6/25 8:33:51 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Truist initiated coverage on Teva Pharma with a new price target

      Truist initiated coverage of Teva Pharma with a rating of Buy and set a new price target of $25.00

      5/28/25 9:09:46 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva Pharma upgraded by Analyst with a new price target

      Analyst upgraded Teva Pharma from Neutral to Overweight and set a new price target of $23.00

      5/12/25 8:18:58 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TEVA
    $SGFY
    Leadership Updates

    Live Leadership Updates

    See more
    • Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations

      Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Company's manufacturing and supply division, effective June 3, 2024. Mr. Shields succeeds Eric Drapé, who is leaving after 11 years with the Company, including more than four years as Executive Vice President, Global Operations. Mr. Shields will be a member of Teva's Executive Leadership Team and report directly to President and CEO Richard Francis. He will be based in Teva's U.S. headquarters in Parsippany, NJ. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2

      5/15/24 8:15:00 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business

      Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. R. Ananthanarayanan (Ananth) as CEO of its Teva Active Pharmaceutical Ingredients business (Teva api). Dr. Ananth will lead the API business starting November 27, 2023, and will be based out of Teva's U.S. headquarters in Parsippany, NJ. Richard Francis, Teva's President and CEO said: "I am excited to welcome Ananth back to Teva to lead the Teva api business during this pivotal time for our company, as we continue to progress on our plan for turning Teva api into a standalone business. We're confident that this strategy will result in a more focused end-to-end operation, and I am confident tha

      11/7/23 4:30:00 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva Announces Changes to Executive Management Team

      Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced changes to its leadership team. Sven Dethlefs, Executive Vice President, North America Commercial, will leave Teva on November 17, 2023, and Christine (Chris) Fox, who most recently served as Global President, Gene Therapies at Novartis will be the new head of Teva's U.S. Commercial Business. "On behalf of the Teva Board of Directors and our executive management team, I want to thank Sven for his many contributions to Teva during his 15 years with the company," said Richard Francis, Teva's President, and Chief Executive Officer, "I am pleased to announce the appointment of Chris Fox to this critical role. Chris is a h

      9/28/23 4:05:00 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care